Treatment of Primary Myelofibrosis with Anaemia and Inadequate Serum Erythropoietin
In primary myelofibrosis, anaemia is a common and clinically significant complication. When the serum erythropoietin level is found to be inadequate — specifically below 500 mU/mL — this laboratory finding becomes a key factor in guiding the therapeutic approach.
Clinical Scenario
This protocol applies to patients with primary myelofibrosis who have anaemia in the setting of an inadequate serum erythropoietin level (<500 mU/mL). Routine practice supports a defined therapeutic trial in this sub-population, where the endogenous erythropoietic response is insufficient.
Treatment Approach
The recommended approach involves a trial of an erythropoiesis-stimulating agent (ESA). The full protocol specifies the agent selection, structured dosing approach, escalation criteria, and trial duration — none of which are detailed here.
Partial overview only — the complete regimen is available via the link below.
Clinical Goal
The primary measure of treatment success is a haemoglobin response, evaluated at 3 months from initiation of therapy.
References
- Serum EPO level. Inadequate. However routine practice would suggest that those with EPO levels <500 mU/mL likely merit an ESA trial for 12 weeks.
- A trial of erythropoiesis-stimulating agents (ESAs), including in combination with ruxolitinib, is recommended for patients with anaemia associated with inadequate erythropoietin levels (Grade 1B).
- ESAs have been used to treat MF with about 50% of patients demonstrating a haemoglobin response.